Taytulla(Norethindrone-E.Estradiol-Iron)
ABBV
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.
$19K
Medicare cost, 2024
$19K
Medicare cost, 2024
Medicare drug plans spent $19,163 on Taytulla (norethindrone-e.estradiol-iron) in 2024, for 45 prescriptions and refills. Spending fell 37% from 2023 to 2024. It is made by AbbVie Inc. (ABBV).
Medicare cost, 2024
$19K
-36.9% from 2023
Prescriptions
45
$425.84 per claim
Patients
-
13 prescribers
Total spending, 2024
$19K
- per patient
Questions and answers
How much does Medicare spend on Taytulla?
Medicare prescription drug plans paid $19K for Taytulla in 2024, for 45 prescriptions and refills to - patients (down 36.9% from 2023). The average cost per claim was $425.84.
Which state spends the most on Taytulla?
Kansas had the highest Medicare cost for Taytulla in 2024: $3,323 for 13 claims.
Who prescribes Taytulla the most?
Douglas S Gleason, obstetrics & gynecology in Topeka, KS, had the highest Medicare cost for Taytulla in 2024: 13 claims costing $3,323.
Who makes Taytulla?
Taytulla is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Allergan Inc..
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Taytulla was $19K in 2024, after a high of $75K in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Taytulla, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Douglas S Gleason Topeka, KS | Obstetrics & Gynecology | 13 | Under 11 | $3,323 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 17 | 73 | 16 | $30K |
| 2023 | 16 | 65 | 13 | $30K |
| 2024 | 13 | 45 | - | $19K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Allergan Inc. | 45 | $19K |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.